• John M Seligson, Alexandra M Patron, Michael J Berger, R Donald Harvey, and Nathan D Seligson.
• Nova Southeastern University, Clearwater, FL, USA.
• Ann Pharmacother. 2021 Jul 1; 55 (7): 921-931.

ObjectiveTo review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.Data SourcesA literature search was conducted utilizing PubMed and MEDLINE databases, applicable published abstracts, and ongoing studies from ClinicalTrials.gov between January 1, 1981, and September 3, 2020. Keywords included sacituzumab govitecan (-hziy), IMMU-132, Trop-2 (trophoblast cell-surface antigen 2), and TACSTD2.Study Selection And Data ExtractionAll English-language trials involving sacituzumab govitecan for mTNBC were included and discussed.Data SynthesisSacituzumab govitecan is an antibody-drug conjugate targeted for Trop-2 and conjugated to the topoisomerase-1 inhibitor SN-38. It was granted accelerated Food and Drug Administration approval based on a phase I/II single-arm, multicenter study (n = 108), which reported an overall response rate of 33.3% and median duration of response of 7.7 months (95% CI = 4.9-10.8 months). Common adverse reactions include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, abdominal pain, and respiratory infection. A confirmatory, randomized phase III clinical trial is ongoing (NCT02574455).Relevance To Patient Care And Clinical PracticeThis review covers the efficacy, safety, and clinical use of sacituzumab govitecan, a third-line drug with activity in mTNBC.ConclusionSacituzumab govitecan is a novel targeted treatment with promising activity in mTNBC.

19 keywords...

hide…